

- Program -
JSH International Liver Conference 2019 “Liver Cirrhosis and Portal Hypertension: Modern Pathophysiology and Emerging Therapies”

Day 1: Tuesday, October 1, 2019

[Room 1]	
08:20-08:30	Opening Remarks <i>Norifumi Kawada (Osaka City University, Japan)</i>
Session I : Epidemiology, Etiology and Basic Knowledge of Liver Cirrhosis and Portal Hypertension	
Moderators: <i>Akio Ido, Junko Tanaka</i>	
08:30-08:50	Stratification of Cirrhosis <i>Massimo Pinzani (UCL, United Kingdom)</i>
08:50-09:10	Historical Review of Innovative Treatments for Portal Hypertension in Japan <i>Naoya Murashima (Mishuku Hospital, Japan)</i>
09:10-09:30	Epidemiology, Etiology and Natural Course of Cirrhosis in Taiwan <i>Jia-Horng Kao (National Taiwan University, Taiwan)</i>
09:30-09:50	Epidemiology, Etiology and Natural Course of Cirrhosis in Vietnam <i>Bui Huu Hoang (University of Medicine and Pharmacy at HCMC city, Vietnam)</i>
09:50-10:00	Discussion
10:00-10:10	Break
Session III : Vascular Biology of Liver Cirrhosis and Portal Hypertension	
Moderators: <i>Goshi Shiota, Yutaka Sasaki, Jordi Gracia-Sancho</i>	
10:10-10:30	Portal Hypertension and Vascular Biology in Liver Disease <i>Don C. Rockey (Medical University of South Carolina, USA)</i>
10:30-10:50	The Pathogenesis of Liver Fibrosis and the Origin of Fibrogenic Myofibroblasts <i>Tatiana Kisselva (UCSD, USA)</i>
10:50-11:10	The Regulation of Hepatic Lymphangiogenesis <i>Yasuko Iwakiri (Yale University, USA)</i>
11:10-11:30	Pathology of Portal Hypertension <i>Masayoshi Kage (Kurume University, Japan)</i>
11:30-11:40	Discussion
11:40-11:50	Break
11:50-12:45	Luncheon Seminar 1 sponsored by AbbVie GK Moderator: <i>Tetsuo Takehara (Osaka University, Japan)</i> Liver Fibrosis in the Post-HCV Era <i>Massimo Pinzani (UCL, United Kingdom)</i>
12:45-14:10	Poster Session Day 1 (11F Room1101-1102)
Late Breaking Research I : Basic (selected oral presentations)	
Moderators: <i>Yasuko Iwakiri, Yasunari Nakamoto, Hirohisa Yano</i>	
14:10-14:25	Selected 1
14:25-14:40	Selected 2
14:40-14:55	Selected 3
14:55-15:10	Selected 4
Session V : Gut-Liver Axis in Cirrhosis and Portal Hypertension	
Moderators: <i>David A Brenner, Hajime Takikawa, Masashi Yoneda</i>	
15:10-15:30	Gut-Liver Axis, Cirrhosis, and Portal Hypertension: the chicken and the egg <i>Vijay H. Shah (Mayo Clinic, USA)</i>
15:30-15:50	Gut-Liver Axis in Cirrhosis and Portal Hypertension <i>Ki Tae Suk (Hallym University, Republic of Korea)</i>
15:50-16:10	The Role of Gut Microbiota in Anti-tumor Immunity in Liver Tumor Microenvironment <i>Naoko Ohtani (Osaka City University, Japan)</i>
16:10-16:30	Gut-Liver Axis in Chronic Liver Diseases <i>Hitoshi Yoshiji (Nara Medical University, Japan)</i>
16:30-16:40	Discussion
16:40-16:50	Break
16:50-17:50	Evening Seminar 1 sponsored by Nihon Pharmaceutical CO., LTD Moderator: <i>Kazuhiko Koike (University of Tokyo, Japan)</i> Portal Vein Thrombosis in Patients with Liver Cirrhosis <i>Hirofumi Kawanaka (National Hospital Organization Beppu Medical Center, Japan)</i>
19:30~	Social Gathering

[Room 2]	
Session II : Extrahepatic Organs in Liver Cirrhosis and Portal Hypertension	
Moderators: <i>Soon Koo Baik, Eiji Tanaka, Nobuyuki Enomoto</i>	
08:30-08:50	Diagnosis and Treatment of Hepatic Encephalopathy <i>Yasuhiro Takikawa (Iwate Medical University, Japan)</i>
08:50-09:10	Diabetes in Cirrhosis and Portal Hypertension, Clinical Implication and Current Challenges <i>Moon Young Kim (Yonsei University Wonju College of Medicine, Republic of Korea)</i>
09:10-09:30	Biliary Disease in Cirrhosis and Portal Hypertension <i>Atsushi Tanaka (Teikyo University, Japan)</i>
09:30-09:50	The Sociology among Liver Cells, Tissues, and Organs in Alcoholic Liver Disease <i>Yoshiyuki Takei (Mie University, Japan)</i>
09:50-10:00	Discussion
10:00-10:10	Break
Session IV : Complications of Liver Cirrhosis and Portal Hypertension	
Moderators: <i>Yutaka Inagaki, Yasuhiro Tanaka, Moon Young Kim,</i>	
10:10-10:30	3-D Imaging for Liver Cirrhosis and Portal Hypertension <i>Takamichi Murakami (Kobe University, Japan)</i>
10:30-10:50	Role of Dual Red Imaging to Esophageal Varices Endoscopic Treatment <i>Yoshihiro Furuichi (Tokyo Medical University, Japan)</i>
10:50-11:10	Treatment of Thrombocytopenia in Advanced Stage Liver Disease (in Europe) <i>Markus Peck-Radosavljevic (Klinikum Klagenfurt, Austria)</i>
11:10-11:30	Bacterial Infection and Acute Kidney Injury in Cirrhosis <i>Kuei-Chuan Lee (Taipei Veterans General Hospital, Taiwan)</i>
11:30-11:40	Discussion
11:40-11:50	Break
11:50-12:45	Luncheon Seminar 2 sponsored by Eisai Co., Ltd & MSD Moderator: <i>Hitoshi Yoshiji (Nara Medical University, Japan)</i> Diagnosis and surveillance for HCC: Present status and future perspective <i>Ryosuke Tateishi (University of Tokyo, Japan)</i> Treatment strategies in advanced HCC – Focus on Lenvatinib - <i>Tatsuya Yamashita (Kanazawa University, Japan)</i>
12:45-14:10	Poster Session Day 1 (11F Room1101-1102)
Late Breaking Research II : Translational (selected oral presentations)	
Moderators: <i>Markus Peck-Radosavljevic, Kenichi Harada, Naoya Kato</i>	
14:10-14:25	Selected 5
14:25-14:40	Selected 6
14:40-14:55	Selected 7
14:55-15:10	Selected 8
Session VI : IVR and Surgical Treatment for Cirrhosis and Portal Hypertension	
Moderators: <i>Shozo Hirota, Mitsuo Shimada, Xiaolong Qi</i>	
15:10-15:30	Surgery and Basic Approach for Portal Hypertension <i>Ken Shirabe (Gunma University, Japan)</i>
15:30-15:50	Surgical Treatment for Portal Hypertension <i>Hiroshi Yoshida (Nippon Medical School, Japan)</i>
15:50-16:10	Portosystemic Shunt Syndrome: Pathogenesis, Hemodynamics, Diagnosis and Endovascular Management <i>Wael Saad (University of Michigan, USA)</i>
16:10-16:30	BRTO in Japan <i>Jun Koizumi (Tokai University, Japan)</i>
16:30-16:40	Discussion
16:40-16:50	Break
16:50-17:50	Evening Seminar 2 sponsored by Bayer Yakuin, Ltd. Moderator: <i>Hiroko Iijima (Hyogo College of Medicine, Japan)</i> Therapeutic Strategy in multiple TKI era <i>Atsushi Hiraoka (Ehime Prefectural Central Hospital, Japan)</i> Clinical impact of sequential therapy in patients with unresectable HCC~ real world data and future perspective~ <i>Kaoru Tsuchiya (Musashino Red Cross Hospital, Japan)</i>
19:30~	Social Gathering

Day 2: Wednesday, October 2, 2019

08:00-08:50 **Morning Seminar 1** sponsored by MSD
Moderator Satoshi Mochida (Saitama Medical University)
Novel Therapeutic Strategies for Liver Fibrosis by Hepatitis C Virus
Kiminori Kimura (Tokyo Metropolitan Komagome Hospital, Japan)
Control and Functional Cure of HBV Infection
Jia-Horng Kao (National Taiwan University, Taiwan)

08:50-09:00 Break
Session VII : Assessment of Liver Cirrhosis and Portal Hypertension I
Moderators: Joan Genesca, Hidetsugu Saito, Shigehiro Kokubu
09:00-09:20 Acute Portal Hypertension Syndromes; an under recognized entity
Shiv Kumar Sarin (Institute for Liver and Biliary Diseases Sciences, India)
09:20-09:40 Accuracy of Viscoelasticity Measurement in Assessing Histologic Parameters in Patients with
Nonalcoholic Fatty Liver Disease Using Shear Wave US Elastography
Fuminori Moriyasu (Sanno Hospital, Japan)
09:40-10:00 Non-invasive Evaluation of Liver Fibrosis
Laurent Castera (Hôpital Beaujon, France)
10:00-10:20 Non-Invasive Diagnosis of Liver Fibrosis by MR Elastography
Masato Yoneda (Yokohama City University, Japan)
10:20-10:30 Discussion
10:30-10:40 Break

Session IX : Assessment of Liver Cirrhosis and Portal Hypertension II
Moderators: Don C. Rockey, Sumiko Nagoshi, Yoshiyuki Ueno
10:40-11:00 Non-invasive Approaches for Diagnosis and Monitoring of Cirrhosis and Portal Hypertension: CHES updates
Xiaolong Qi (Lanzhou University, China)
11:00-11:20 Non Invasive Assessment of Varices and CspH in Compensated Advanced Chronic Liver Disease Patients
Joan Genesca (Universitat Autònoma de Barcelona, Spain)
11:20-11:40 Mac-2 Binding Protein, as Glycobiomarker of Liver Fibrosis and its Biological Function
Eiji Miyoshi (Osaka University, Japan)
11:40-12:00 Macrophages and NK Cells as a Source of Biomarkers in Patients with NAFLD
Tatsuya Kanto (National Center for Global Health and Medicine, Japan)
12:00-12:10 Discussion
12:10-12:20 Break

12:20-13:20 **Luncheon Seminar 3** sponsored by Gilead Sciences
Moderator Yoichi Hiasa (Ehime University, Japan)
Update on liver fibrosis and cirrhosis
Vincent WS Wong (The Chinese University of Hong Kong, China)

13:20-14:45 **Poster Session 2 (11F Room1101-1102)**
Late Breaking Research III: Clinical Diagnosis (selected oral presentations)
Moderators: Vijay Shah, Fumitaka Suzuki, Takuji Torimura
14:45-15:00 Selected 9
15:00-15:15 Selected 10
15:15-15:30 Selected 11
15:30-15:45 Selected 12
15:45-16:00 Selected 13

Session XI: Emerging Therapies for Liver Cirrhosis and Portal Hypertension II
Moderators: Tatiana Kisselva, Yoshito Itoh, Laurent Castera
16:00-16:20 Development of Anti-Fibrotic Drugs
David A Brenner (UCSD, USA)
16:20-16:40 Clinical Features of Sarcopenia in Patients with Chronic Liver Disease and Efficacy of Intervention with BCAA and Exercise
Atsushi Hiraoka (Ehime Prefectural Central Hospital, Japan)
16:40-17:00 Real-World Experience of Lusutrombopag for Cirrhotic Patients with Low Platelet Counts Prepared for Invasive Pures
Namiki Izumi (Musashino Red Cross Hospital, Japan)
17:00-17:20 Stem Cell Therapy For Liver Cirrhosis: Basic Study And Clinical Trial
Shuji Terai (Niigata University, Japan)
17:20-17:40 Transplantation of Mesenchymal Stem Cell as A New Therapeutic Option In Hepatic Fibrosis
Soon Koo Baik (Yonsei University Wonju College of Medicine, Republic of Korea)
17:40-17:50 Discussion
17:50-18:00 **Closing Remarks**
Shigehiro Kokubu (Shin Yurigaoka Hospital, Japan)

08:00-08:50 **Morning Seminar 2** sponsored by Otsuka Pharmaceutical
Moderator Kiwamu Okita (Shunan Memorial Hospital, Japan)
Total management of cirrhosis
Koichi Takaguchi (Kagawa Prefectural Central Hospital, Japan)
08:50-09:00 Break

Session VIII : Do Portal Hypertension Regress?
Moderators: Kiyoshi Hasegawa, Etsuro Hatano, Tung-Hung Su
09:00-09:20 Regression of Portal Hypertension: Cellular and Molecular Mechanisms
Jordi Gracia-Sancho (IDIBAPS & CIBEREHD, Spain)
09:20-09:40 Regression of Portal Hypertension: Viral Hepatitis
Masayuki Kurosaki (Musashino Red Cross Hospital, Japan)
09:40-10:00 Does Portal Hypertension Regress? – Nonalcoholic Steatohepatitis
Vincent WS Wong (The Chinese University of Hong Kong, China)
10:00-10:20 Surgical Procedures for Portal Hypertension and NAFLD/NASH
Masayuki Ohta (Oita University, Japan)
10:20-10:30 Discussion
10:30-10:40 Break

Session X: Emerging Therapies for Liver Cirrhosis and Portal Hypertension I
Moderators: Wael Saad, Naoya Sakamoto, Kenichi Ikejima
10:40-11:00 Real World Ascites Treatment in Japan
Masanori Atsukawa (Nippon Medical School, Japan)
11:00-11:20 A New Era of Treatment with Antithrombin Therapy for Portal Vein Thrombosis
Hisashi Hidaka (Kitasato University, Japan)
11:20-11:40 Muscle Clumps and Sarcopenia
Takumi Kawaguchi (Kurume University, Japan)
11:40-12:00 Effects of BCAA on Prevention of Liver Failure and Carcinogenesis in Patients with Cirrhosis
Masahito Shimizu (Gifu University, Japan)
12:00-12:10 Discussion
12:10-12:20 Break

12:20-13:20 **Luncheon Seminar 4** sponsored by Sysmex Corporation
Moderator Masaru Harada (University of Occupational and Environmental Health, Japan)
Prediction of liver fibrosis progression and HCC development in NAFLD
Keisuke Hino (Kawasaki Medical School, Japan)
Remaining issues in post-virus hepatitis era-Usefulness of biomarkers in hepatic carcinogenesis and portal hypertension
Hiroshi Yatsushashi (Nagasaki Medical Center, Japan)

13:20-14:45 **Poster Session 2 (11F Room1101-1102)**
Late Breaking Research IV: Clinical Therapy (selected oral presentations)
Moderators: Kazuhiko Nakao, Mitsuhiko Moriyama Hiroshi Yotsuyanagi
14:45-15:00 Selected 14
15:00-15:15 Selected 15
15:15-15:30 Selected 16
15:30-15:45 Selected 17
15:45-16:00 Selected 18

Session XII: Emerging Therapies for Liver Cancer from Cirrhosis
Moderators: Shiv Kumar Sarin, Norihiro Kokudo, Hiroaki Nagano
16:00-16:20 Occurrence of Hepatocellular Carcinoma from Cirrhosis
Tung-Hung Su (National Taiwan University Hospital, Taiwan)
16:20-16:40 Pathology Diagnosis of Tumor Microenvironment of HCC
Michiie Sakamoto (Keio University, Japan)
16:40-17:00 Prevention and Risk for Liver Cancer after Anti-Viral Therapy in Patients with HBV/HCV
Yasuhiro Asahina (Tokyo Medical and Dental University, Japan)
17:00-17:20 Development of Immunotherapy for Hepatocellular Carcinoma
Eishiro Mizukoshi (Kanazawa University, Japan)
17:20-17:40 Molecular Targeted Therapy for Liver Cancer
Masatoshi Kudo (Kindai University, Japan)
17:40-17:50 Discussion